MedStar Health Raises the Bar on Emerging Field of Immuno-oncology
January 29, 2018
Pallavi P. Kumar, MD Named Director of Immuno-oncology, MedStar Health Cancer Network
BALTIMORE, Md.—(January 29, 2018)— Pallavi P. Kumar, MD, has been named director of Immuno-Oncology for the Baltimore region of the MedStar Health Cancer Network, leading a charge to optimize immune based therapies and clinical trials, and advance the standard of care in the treatment of cancer.
Immunotherapy, actively used in the cancer research, is a treatment that boosts the body’s immune system and helps train it to attack cancer cells. It has changed the landscape of oncology, enabling patients to live longer lives.
Clinical trials in immuno-oncology first started at MedStar Franklin Square Medical Center in 2007. “We are an academic-hybrid community hospital with an enormous amount of experience in immunotherapy,” said Dr. Kumar. “We benefit from the collaborative work with the MedStar Georgetown Lombardi Comprehensive Cancer Center and the Cancer Institute at Medstar Washington Hospital Center.”
In her new role, Dr. Kumar, who specializes in many solid tumors, including melanoma, head and neck, sarcoma, gastrointestinal, gynecologic and urologic malignancies at Medstar Franklin Square, will lead immuno-oncology clinical trial efforts for all cancers, collaborate with regional physicians to find new therapies for patients, and profile tumors to optimize treatments. She will continue to oversee research that test new combinations of immunotherapy with surgery, chemotherapy, and radiation. These strategies can offer hope to patients that their cancers might become chronic diseases, or even be cured.
“This new position bolsters the work Dr. Kumar has already been doing at MedStar for years,” said Albert Aboulafia, medical director of the Weinberg Cancer Institute at MedStar Franklin Square Medical Center and the Baltimore Region. “She has helped build our immuno-oncology program into what it is today and is dedicated to getting the best outcomes for our patients.”
“We want the community to be aware that we have invested in clinical trials, molecular profiling and treatments that pioneer novel therapies for cancer patients,” Dr. Kumar said. “The comprehensive team approach throughout the Medstar Health network, provide meaningful outcomes in the lives of our patients.”
Click here for more information on the MedStar Health Cancer Network.
Back to Top